Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
869
Views
25
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)

Othman S. AkhtarDepartment of Medicine, State University of New York at Buffalo, Buffalo, NY, USA; Correspondence[email protected]
,
Kristopher AttwoodDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;
,
Ian LundDepartment of Medicine, Division of Lymphoma/Myeloma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;
,
Ryan HareRoswell Park Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
,
Francisco J. Hernandez-IlizaliturriDepartment of Medicine, State University of New York at Buffalo, Buffalo, NY, USA; ;Department of Medicine, Division of Lymphoma/Myeloma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;
&
Pallawi TorkaDepartment of Medicine, State University of New York at Buffalo, Buffalo, NY, USA; ;Department of Medicine, Division of Lymphoma/Myeloma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;
Pages 1650-1655 | Received 19 Aug 2018, Accepted 28 Nov 2018, Published online: 02 Jan 2019

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Rania S. Khelifi, Steven J. Huang, Kerry J. Savage, Diego Villa, David W. Scott, Khaled Ramadan, Joseph M. Connors, Laurie H. Sehn, Cynthia L. Toze & Alina S. Gerrie. (2023) Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada. Leukemia & Lymphoma 64:6, pages 1129-1138.
Read now
James Collins$suffix/text()$suffix/text(), Sarah E. Stump, Hillary Heiling, Michele Muir, Allison Deal, Darrian Proco, Catharine Nguyen, Monica Cozad, Anthony Mato, Catherine C. Coombs & Benyam Muluneh. (2022) Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 63:8, pages 1823-1830.
Read now
Stefano Molica, Valentina Gianfelici & Luciano Levato. (2020) Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. Expert Opinion on Emerging Drugs 25:1, pages 25-35.
Read now
Prithviraj Bose, Lisa S. Chen & Varsha Gandhi. (2019) Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the ‘real world’. Leukemia & Lymphoma 60:7, pages 1603-1605.
Read now

Articles from other publishers (21)

Soroush Fariman, Fatemeh Momeni Nasab, Hoda Faraji & Monireh Afzali. (2023) Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran. Value in Health Regional Issues 38, pages 93-100.
Crossref
Jacqueline C. Barrientos, Ayed O. Ayed, Agnes Cha, Senxi Du, Bruno Fang, Ryan Hall, Stanley M. Marks, Eileen Peng, Joanna M. Rhodes, Kellie Ryan, Sharon B. Winters, Percy L. Yeung & Jing-Zhou Hou. (2023) Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences. Targeted Oncology.
Crossref
Eman I. K. Ibrahim, Mats O. Karlsson & Lena E. Friberg. (2023) Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Shayna Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon & Jorge J. Castillo. (2023) Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. British Journal of Haematology 201:5, pages 897-904.
Crossref
Jennifer A. Woyach, Paul M. Barr, Thomas J. Kipps, Jacqueline C. Barrientos, Inhye E. Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain & Jan A. Burger. (2023) Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study. Cancers 15:2, pages 507.
Crossref
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Clara Deambrogi, Silvia Rasi, Francesco Autore, Michele Merli, Roberta Mattarucchi, Gaby Fahrni, Lydia Scarfo’, Daniela Gussetti, Pietro Bulian, Annagiulia Zanatta, Valeria Spina, Alessio Bruscaggin, Katia Pini, Deborah Piffaretti, Maria Cristina Pirosa, Matin Salehi, Joyce Marques de Almeida, Jakob Passweg, Franco Cavalli, Emanuele Zucca, Bernhard Gerber, Georg Stussi, Valter Gattei, Paolo Ghia, Michael Gregor, Francesco Passamonti, Luca Laurenti, Gianluca Gaidano, Alessandra Tedeschi, Davide Rossi & Adalgisa Condoluci. (2022) Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia. Hematological Oncology 40:5, pages 1100-1104.
Crossref
Åsmund Flobak, Sigrid S. Skånland, Eivind Hovig, Kjetil Taskén & Hege G. Russnes. (2022) Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends in Pharmacological Sciences 43:11, pages 973-985.
Crossref
Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang & Michael Choi. (2022) Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clinical Lymphoma Myeloma and Leukemia 22:11, pages e959-e971.
Crossref
Sigrid S. Skånland & Geir E. Tjønnfjord. (2022) Determining drug dose in the era of targeted therapies: playing it (un)safe?. Blood Cancer Journal 12:8.
Crossref
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps & Paolo Ghia. (2022) Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances 6:11, pages 3440-3450.
Crossref
Jing-Zhou Hou, Kellie Ryan, Senxi Du, Bruno Fang, Stanley Marks, Ray Page, Eileen Peng, Keith Szymanski, Sharon Winters & Hannah Le. (2021) Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncology 17:35, pages 4959-4969.
Crossref
Stefanie L. Groenland, Mark J. Ratain, Lisa S. Chen & Varsha Gandhi. (2021) The Right Dose: From Phase I to Clinical Practice. American Society of Clinical Oncology Educational Book:41, pages 92-106.
Crossref
Philipp von Hundelshausen & Wolfgang Siess. (2021) Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers 13:5, pages 1103.
Crossref
Sigrid S. Skånland & Anthony R. Mato. (2021) Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Advances 5:1, pages 334-343.
Crossref
Paul J. Hampel, Timothy G. Call, Kari G. Rabe, Wei Ding, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Jose F. Leis, Thomas E. Witzig, Amber B. Koehler, Amie L. Fonder, Susan M. Schwager, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay & Sameer A. Parikh. (2020) Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. The Oncologist 25:11, pages 974-980.
Crossref
Sigrid S. Skånland, Linda Karlsen & Kjetil Taskén. (2020) B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia. Scandinavian Journal of Immunology 92:5.
Crossref
Abraham M. Varghese, Nitin Sood & Sunitha M. Daniel. (2020) Current pricing model for cancer drugs ‒ is it ‘Justum Pretium’ for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration. British Journal of Haematology 190:5.
Crossref
Prioty Islam & Anthony R. Mato. (2020) Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. Current Hematologic Malignancy Reports 15:4, pages 254-260.
Crossref
Stefano Molica, Estella Matutes, Constantine Tam & Aaron Polliack. (2020) Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematological Oncology 38:2, pages 129-136.
Crossref
Prioty Islam & Anthony R. Mato. (2019) Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies. The Cancer Journal 25:6, pages 442-448.
Crossref
. (2019) Ibrutinib. Reactions Weekly 1764:1, pages 162-162.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.